Domains of methylated CAC and CG target MeCP2 to tune transcription in the brain

Sabine Lagger, John Connelly, Gabriele Schweikert, Shaun Webb, Jim Selfridge, Bernard Ramsahoye, Miao Yu, Dina DeSousa, Christian Seiser, Chuan He, Guido Sanguinetti, Lawrence C. Sowers, Malcolm D. Walkinshaw, Adrian BirdbioRxiv 2016 · DOI

Abstract

Mutations in the gene encoding the methyl-CG binding protein MeCP2 cause neurological disorders including Rett syndrome. The di-nucleotide methyl-CG (mCG) is the canonical MeCP2 DNA recognition sequence, but additional targets including non-methylated sequences have been reported. Here we use brain-specific depletion of DNA methyltransferase to show that DNA methylation is the primary determinant of MeCP2 binding in mouse brain. In vitro and in vivo analyses reveal that MeCP2 binding to non-CG methylated sites in brain is largely confined to the tri-nucleotide sequence mCAC. Structural modeling suggests that mCG and mCAC may be interchangeable as minimal structural perturbation of MeCP2 accompanies binding. MeCP2 binding to chromosomal DNA in mouse brain is proportional to mCG + mCAC density and defines domains within which transcription is sensitive to MeCP2 occupancy. The results suggest that MeCP2 interprets patterns of mCAC and mCG in the brain to negatively modulate transcription of genes critical for neuronal function.

Introduction

The protein MeCP2 is a critical regulator of neuronal maturation and function. Its clinical significance is underscored by the fact that loss-of-function mutations in the MECP2 gene lead to Rett syndrome, a severe neurodevelopmental disorder. While MeCP2 has long been recognized as a reader of methylated DNA—specifically methylated cytosine-guanine (mCG) dinucleotides—the full scope of its genomic targets in the brain has remained a subject of intense debate. Previous studies have suggested potential affinities for non-methylated DNA, hydroxymethylated DNA (hmC), or various non-CG methylated sequences. This study clarifies these interactions, identifying methylated CAC (mCAC) as a primary target that, alongside mCG, dictates MeCP2 distribution and its role as a transcriptional "dimmer switch."

Determining the Primary Drivers of Binding

To resolve the ambiguity surrounding MeCP2 recruitment, researchers utilized a mouse model with brain-specific depletion of the DNA methyltransferase Dnmt1. By reducing global DNA methylation by approximately 40%, the team observed a commensurate loss of MeCP2 binding across the genome. This genetic evidence confirms that DNA methylation is the indispensable primary determinant of MeCP2 recruitment in the living brain, effectively ruling out non-methylated DNA as a significant physiological target.

Further biochemical analysis using Electrophoretic Mobility Shift Assays (EMSA) tested MeCP2's affinity for all possible tri-nucleotide combinations. The results revealed a striking specificity: among non-CG sites, MeCP2 selectively targets mCAC. Other variations, such as mCAG or mCAA, showed poor binding affinity. This specificity is biologically significant because mCAC is the most prevalent form of non-CG methylation in the adult brain, accumulating postnatally as neurons mature.

Structural Basis for Dual Recognition

The ability of a single protein domain—the Methyl-Binding Domain (MBD)—to recognize two distinct DNA sequences (mCG and mCAC) was explored through structural modeling. Using existing X-ray crystallography data, the study identified Arginine 133 (R133) as a key molecular pivot. This residue acts as a flexible hinge, capable of tilting to interact with the guanine in an mCG pair or the guanine paired with the third cytosine in an mCAC motif. This minimal structural perturbation allows MeCP2 to treat mCG and mCAC as essentially interchangeable targets, expanding its regulatory reach without requiring multiple binding domains.

Notably, the study found no evidence for the "AT-flank" requirement—a previously proposed theory that MeCP2 requires AT-rich sequences adjacent to its target sites. In the context of the brain's complex chromatin environment, the presence of the methyl mark itself appears to be the dominant signal for recruitment.

Genomic Domains and Transcriptional Regulation

By combining high-resolution Whole Genome Bisulfite Sequencing (WGBS) with ChIP-seq, the researchers demonstrated that MeCP2 occupancy is almost perfectly proportional to the combined density of mCG and mCAC. Rather than binding solely to isolated promoters, MeCP2 coats massive genomic "domains" that can span up to 1 megabase (Mb) in length.

These domains function as repressive landscapes. Genes located within high-occupancy MeCP2 domains are typically up-regulated when MeCP2 is absent (knockout models) and down-regulated when MeCP2 is over-expressed. This suggests that MeCP2 does not act as a simple binary on/off switch but rather as a global modulator that tunes down the expression of genes within its territory. Long genes, which are essential for neuronal function and contain a high density of these methylation marks, appear particularly sensitive to this regulation.

Conclusion and Future Directions

This research establishes a definitive map of MeCP2 binding, highlighting the synergy between mCG and mCAC in the brain. While the study clarifies the "rules" of MeCP2 recruitment, several questions remain. The observed 15% reduction in total RNA in MeCP2-deficient brains suggests a complex relationship between global transcription and specific gene regulation that requires further study. Additionally, future work must determine if these domain-level regulatory rules are consistent across different neuronal subtypes and glia, or if cell-specific methylation patterns create unique regulatory landscapes across the brain.

Summary updated

Abstract

Summary Mutations in the gene encoding the methyl-CG binding protein MeCP2 cause neurological disorders including Rett syndrome. The di-nucleotide methyl-CG (mCG) is the canonical MeCP2 DNA recognition sequence, but additional targets including non-methylated sequences have been reported. Here we use brain-specific depletion of DNA methyltransferase to show that DNA methylation is the primary determinant of MeCP2 binding in mouse brain. In vitro and in vivo analyses reveal that MeCP2 binding to non-CG methylated sites in brain is largely confined to the tri-nucleotide sequence mCAC. Structural modeling suggests that mCG and mCAC may be interchangeable as minimal structural perturbation of MeCP2 accompanies binding. MeCP2 binding to chromosomal DNA in mouse brain is proportional to mCG + mCAC density and defines domains within which transcription is sensitive to MeCP2 occupancy. The results suggest that MeCP2 interprets patterns of mCAC and mCG in the brain to negatively modulate transcription of genes critical for neuronal function.
BibTeX
@misc{lagger2016domains,
  author = {Sabine Lagger and John Connelly and Gabriele Schweikert and Shaun Webb and Jim Selfridge and Bernard Ramsahoye and Miao Yu and Dina DeSousa and Christian Seiser and Chuan He and Guido Sanguinetti and Lawrence C. Sowers and Malcolm D. Walkinshaw and Adrian Bird},
  title = {{Domains of methylated CAC and CG target MeCP2 to tune transcription in the brain}},
  year = {2016},
  doi = {10.1101/087577},
  howpublished = {bioRxiv},
}
Figure